Background. In previous work, the four-amino analogue of tetrahydrobiopterin, a novel, selective inhibitor of inducible nitric oxide synthase, has been shown to prolong survival of murine cardiac allografts. Methods. To further elucidate the underlying molecular immunosuppressive mechanism, we compared the effect of four-amino tetrahydrobiopterin with that of the unsubstituted parent compound tetrahydrobiopterin and of N 6 -(iminoethyl)-L-lysine (L-NIL), a nonpterin inhibitor of inducible nitric oxide synthase using a murine cardiac transplant model. We analyzed allograft survival, intragraft gene expression in grafts by microarray and real-time polymerase chain reaction, graft nitrotyrosine staining by immunohistochemistry and plasma nitrite plus nitrate levels by high-performance liquid chromatography. Results. Allograft survival was significantly prolonged by tetrahydrobiopterin and cyclosporin A, but not by L-NIL although decreased plasma nitrite plus nitrate levels confirmed nitric oxide synthase inhibition in vivo. As compared to allogeneic untreated controls, intragraft peroxynitrite formation and hence nitrotyrosine staining was lowered in all groups except in cyclosporine A-treated animals. Gene expression profiles obtained by microarray analysis demonstrated that cyclosporine A was able to counteract the expression changes of more than half of the genes differently expressed in syngeneic grafts versus allografts, whereas tetrahydrobiopterin compounds and L-NIL showed only smaller influences on gene expression profiles.
A cute rejection following solid organ transplantation is a complex immunological phenomenon involving a variety of potential mediators. Although caused primarily by T-cells, various other cell populations and subpopulations, lymphokines and cytokines, adhesion molecules as well as intracellular signal transduction pathways also contribute to orchestrate a complete immune response, and several agents interfering with this immune response have been developed (1, 2) . Among the mechanisms contributing to rejection, nitric oxide (NO) generated by the inducible isoform of NO-synthases (iNOS) is thought to play a key role in acute rejection (3) . For cardiac allograft rejection, iNOS mRNA expression, protein and enzyme activity were found to be massively up-regulated or induced in infiltrating macrophages and cardiac myocytes and to contribute substantially to cellular injury and inflammation (4) . On the other hand, NO is known to be cardioprotective (5) . In addition, NO has been identified as a mediator of the positive effects of ischemic preconditioning (6) .
In line with this dichotomy of NO action, the data concerning treatment with different NOS-inhibitors are still conflicting and have shown to either prolong graft survival, have no effect on, or even impair allograft survival (7) (8) (9) . Currently, it is not clear whether these differences are due to different pharmacology and/or specificity of the NOS-inhibitors, and the underlying molecular mechanisms by which iNOS-inhibitors act immunosuppressively are still not known in detail.
The four-amino-analogue of tetrahydrobiopterin (ABH4) is a derivative of the tetrahydrobiopterin cofactor (BH4) of nitric oxide synthase (NOS), that was designed to investigate the mechanism of stimulation of the enzyme by tetrahydrobiopterin (10) . ABH4 was found to bind to the enzyme with high affinity, to inhibit its activity in competition with tetrahydrobiopterin and to preferentially inhibit the inducible isoform of NOS in tissue culture and in aortic strips (11, 12) . In rats, a single bolus dose of the compound saved the animals from lethal effects of endotoxin (13, 14) . Recently, we were able to demonstrate in a murine cardiac transplant model that ABH4 significantly prolongs graft survival with an efficacy comparable to that of high-dose CsA treatment, but with a mechanism apparently different from calcineurin inhibition (15) . However, the immunosuppressive features of ABH4 in vivo and the mechanisms by which it might regulate intragraft gene expression to permit prolonged allograft survival are still not fully understood.
The present study therefore compared the action of ABH4 to that of the NOS-stimulatory-parent-compound BH4 and the nonpterin-based iNOS-inhibitor N 6 -(iminoethyl)-L-lysine (L-NIL) and CsA to estimate the contribution of iNOS inhibition to the immunosuppressive action tetrahydrobiopterin derivatives.
MATERIALS AND METHODS

Animal Experiments
All animals received humane care in compliance with the "Principles of Laboratory Animal Care" formulated by the National Society for Medical Research and the "Guide for the Care and Use of Laboratory Animals," prepared by the National Academy of Sciences and published by the National Institute of Health (NIH Publication No. 86-23, revised 1985) . All experiments were approved by the Austrian Ministry of Education, Science and Culture.
Animals
Two fully allogeneic strains of inbred, male mice, C57BL/10 (H2 b ) and C3H/He (H2 k ), were obtained from Harlan-Winkelmann Co. (Borchen, Germany).
Heart Transplantation
Cervical heterotopic heart transplantation was performed with a modified cuff-technique for revascularization as previously described (15, 16) . Cardiac allograft survival was determined by daily palpation and binocular inspection, with complete cessation of heart beats indicating severe rejection, which was confirmed by histology.
Graft Function Scoring
Heart performance was scored according to the criteria summarized in Table 1 .
Treatment and Sample Collection
Groups of 5-10 animals each were treated for 7 days following transplantation with either ABH4 (50 mg/kg every 8 hr), BH4 (50 mg/kg every 8 hr), L-NIL (5 mg/kg every 8 hr), CsA (Novartis, Inc., Basel, Switzerland; 15 mg/kg every 24 hr), or remained untreated. All substances were dissolved in phosphate-buffered saline and administered intramuscularly. ABH4 and BH4 are not stable for prolonged times in these solutions and have therefore been always freshly dissolved immediately prior to injection. No antioxidants have been added. Mice were sacrificed with an overdose of anesthetics on postoperative days 1 or 6 and the transplants removed for intragraft gene expression profiling and histological evaluation. Hearts were processed for blinded evaluation by one pathologist according to the ISHLT grading system (17) . Mice used for survival analysis were killed on the day of graft failure. Corresponding plasma samples were harvested for nitrate and nitrite measurements by HPLC. Tissue samples were either immediately frozen in liquid nitrogen and stored at Ϫ75°C until further analysis for gene expression, or were fixed in formalin and embedded in paraffin until analyzed by hematoxylin and eosin staining or immunohistochemistry.
Analysis of Nitrotyrosine Staining in Tissue Sections
Graft sections (4 m) were cut from paraffin blocks, mounted on slips and the paraffin removed by heating in citrate buffer, pH 6.0. Endogenous peroxidase was blocked by hydrogen peroxide. Immunohistochemistry was then performed in a DAKO autostainer (DAKO, Copenhagen, Denmark), using the antinitrotyrosine rat polyclonal antibody from Upstate Biotechnology (Lake Placid, NY) at 1:100 dilution. For staining, secondary antibody peroxidase labeled polymer and 3,3= diaminobenzidine tetrahydrochloride (DAKO) were used. Haemalaun was used for counter-staining. For quantification, the proportion of positive cells in quartiles (0, 1, 2, 3, 4) was multiplied by the staining intensity (0, no staining; 1, weak; 2, moderate; 3, strong) yielding a total immunostaining score ranging from 0 to 12.
Analysis of Intragraft Gene Expression Profiles
Total RNA was extracted from tissue sections (cubes of approximately 3 mm) using Trizol (Gibco, Invitrogen, Lofer, Austria). For gene-array-analysis, RNA was pooled (five animals each) and analyzed by vbc-genomics (Vienna, Austria) using labeled cRNAs with the Affymetrix System, employing mouse 430A-arrays, which probe 22626 mouse mRNAs (Affymetrix, High Wycombe, United Kingdom). Sample preparation and processing was done according to the Affymetrix protocols by Vienna Biosystems Corporation. Briefly, total RNA was converted to first strand DNA with Superscript II reverse transcriptase, using an T7-(dT)24 primer. Second strand cDNA synthesis was achieved with E. coli T4 DNA ligase, E. coli DNA polymerase I and RNAse H (all from Invitrogen). After purification with ethanol/chloroform extraction, biotin labeled cRNA was prepared using the Enzo bioarray high yield RNA transcript labeling kit (Affymetrix). Fragmentation of cRNA was achieved by incubation at 94°C for 35 min. Slides were hybridized in presence of herring sprem DNA together with the hybridization control genes BioB, BioC, BioD and cre from E. coli (Affymetrix). Slides were stained with streptavidin-phycoerythrin and scanned in an Affymetrix Scanner. In the Affymetrix gene array slides, each mRNA is probed by 11 pairs of probes, each pair con- 
Hearts were evaluated by two surgeons in a blinded fashion, and scoring was completed before a different scientist harvested the grafts. taining a perfect match and a mismatch probe, respectively. Combinations of genes classified by the Affymetrix software as absent were excluded from analysis of differential gene expression. A factor of two was set as threshold for differences in gene expression.
For real-time quantitative PCR, 500 ng of RNA was reverse-transcribed (Superscript II, Invitrogen), and gene expression quantified in relation to 18S ribosomal RNA using the Taqman-technique in an ABI Prism 7700 Sequence Detector Instrument (Applied Biosystems, Vienna, Austria). Sequences of primers and probes (3= FAM, 5=-TAMRA label, synthesized by Microsynth, Balgach, Switzerland) are available on request from the corresponding author.
Analysis of Plasma Nitrite Plus Nitrate
Plasma nitrite plus nitrate were determined using a method modified after Green et al. employing ultrafiltration and HPLC separation, online mixing with the Griess reagent and UV detection at 546 nm (18) .
Statistics
Kruskal Wallis statistics with Dunn's positive test for comparison of all groups were used for statistical analysis of all data. P values of Ͻ0.05 were judged significant.
RESULTS
Graft Survival
The impact of the various treatment regimens on cardiac allograft survival is summarized in Figure 1 . Untreated allografts were rejected around days 7 and 8 posttransplantation (mean graft survival time: 7.1Ϯ0.7 days), whereas all syngeneic grafts showed indefinite survival (Ͼ100 days). CsA prolonged allograft survival to 14.0Ϯ1.8 days (PϽ0.001 compared to survival of untreated allografts) The iNOS-inhibitor L-NIL did not extend allograft survival beyond that of untreated controls (7.4Ϯ0.5 days). Four-amino tetrahydrobiopterin derivatives prolonged allograft survival to 9.9Ϯ2.4 days, but this increase was not significant by the Kruskal Wallis test employed. Surprisingly, tetrahydrobiopterin prolonged survival even somewhat better than the four-amino derivative to 12.3Ϯ4.9 days (PϽ0.05 different from untreated allografts; Figure 1 ).
Graft Function on Day 6 Posttransplantation
All syngeneic grafts showed a heart function score of 4 on postoperative day 6, whereas untreated allografts (score 2.33Ϯ0.58) and L-NIL-treated allografts (score 2.40Ϯ0.55) revealed impaired graft function. In contrast, CsA therapy (score 3.80Ϯ0.44), treatment with ABH4 (score 3.40Ϯ0.55) and BH4 (score and 3.60Ϯ0.55) yielded average cardiac scores statistically closer to that of syngeneic controls (score 4.0). Differences were, however, not significant by the Kruskal Wallis test employed in this study.
Histological Evaluation
On day 1 posttransplantation, no differences were seen in terms of cellular infiltration between control allografts, treated allografts, and syngeneic grafts (all ISHLT-scores, 0-IA). On day 6 posttransplantation, untreated and allografts treated with L-NIL showed diffuse, perivascular, or interstitial infiltrates with myocyte damage and focal necrosis (ISHLT-score untreated control: IV; ISHLT-score L-NIL: IIIB). CsA-treated allografts revealed almost no cellular infiltrates on day 6 posttransplantation (ISHLT-scores: IA). By contrast, despite good myocardial function, all ABH4-as well as BH4-treated hearts showed infiltrates of mononuclear cells and some foci of inflammatory infiltrate resulting in ISHLTscores for ABH4 (IIIA to IIIB) and BH4 (IB to IIIA). None of the isografts showed histological signs of rejection (all ISHLT scores: 0).
Plasma Nitrite and Nitrate Concentrations
To monitor the effect of the applied treatment regimens on NO-production, we assessed plasma nitrite plus nitrate levels on days 1 and 6 posttransplantation (Fig. 2) . Whereas all groups showed levels similar to syngeneic controls on postoperative day 1, nitrate and nitrite concentrations were found to be elevated on day 6 in recipient animals of untreated allografts and in animals treated with BH4. When compared to untreated allografts, ABH4 as well as L-NIL treatment showed inhibition of NO-production with lower plasma nitrite plus nitrate levels, which did not differ from those seen in syngeneic controls. Treatment with CsA resulted in plasma nitrate and nitrite concentrations that ranged between the levels observed in untreated allograft recipients and those of syngeneic controls. With the nonparametric Kruskal Wallis test employed here, however, only the difference between L-NIL at 24h and the allogeneic combination at day 6 yielded statistical significance (Fig. 2) . 
Microarray
Using total RNA extracted from allograft tissue harvested on day 6 posttransplantation, we screened for changes in intragraft gene expression by means of the Affymetrix 430A expression array. In all, 14,151 (62%) of the 22,626 genes were detected, judged present by the Affymetrix software, at least in one of the six RNA samples pooled from five animals each. The complete results set is available from GEO (http:// www.ncbi.nlm.nih.gov/geo/ accession number GSE1809, see ref. 19 for database description and data display and data mining options).
We first compared gene expression profiles between the syngeneic graft and the allograft on day six posttransplant. For heart grafts of allogeneic untreated animals, 1,115 genes were expressed differently as compared to grafts of untreated syngeneic animals. Increased expression was detected for 576 genes in untreated allograft heart tissue. Many of these 576 genes are well known mediators of immune responses, such as inflammatory cytokines, chemokines, and their receptors including interferon (IFN)-␥, immune response gene 1, IL-2R␤, tumor necrosis factor (TNF)-R9, MHC class I H-2Ds, T cell receptor (TCR)-beta chain, CD3 antigen, programmed cell death 1 ligand 1, SCYB11, and granzyme B. In addition, 539 genes showed decreased expression levels between twoand more than 16-fold. These included different growth factors and their receptors: platelet-derived growth factor (PDGF)-R␣, insulinlike growth factor (IGF)-1, insulinlike growth factor binding protein (IGF-BP) 4, 5 and 7; matrix metalloproteinases (MMPs): MMP-2, tissue inhibitor of MMP-2, MMP-14, and MMP-23; chemokines: CXC chemokine MIP-2 gamma precursor, small inducible cytokine A21a, B cell, and mononcyte-activating chemokine precursor.
CsA was able to efficiently reverse the regulation of more than half of the genes with altered expression in the untreated heart allografts as compared to the syngeneic controls. Reversal was found for 640 of the 1,115 genes (285 of the 576 genes with increased expression, 355 of the 539 repressed genes). In contrast to CsA, the other treatment regimens had only small effects on intragraft gene expression at day 6 posttransplantation. Of the 1,115 differentially expressed genes in the allograft as compared to the syngeneic graft, only 28 genes were counter-regulated by 4-amino tetrahydrobiopterin, 148 by tetrahydrobiopterin and 16 by L-NIL. Most of these counter-regulated genes were shared with CsA (28 of 28 for 4 amino-tetrahydrobiopterin, 86 of 148 for tetrahydrobiopterin, and 11 of 16 for L-NIL). CsA action, and to a lesser extent BH4 action, was focused on genes with altered expression in allografts as compared to syngeneic grafts. Of the total of 808 genes affected by CsA, 640 (79%) belonged to this class, whereas only 168 of the genes affected by CsA showed similar expression in syngeneic grafts and in allografts. Of the total of 203 genes affected by BH4, 128 (63%) showed altered expression in allografts as compared to syngeneic grafts. In contrast, the other treatment regimens did not primarily affect genes altered on allograft versus syngeneic graft: ABH4, for example, regulated 70 genes in total, only 28 (40%) of which were altered in allografts as compared to syngeneic grafts (see above). L-NIL regulated 94 genes in total, only 16 (17%) of these were altered in allografts as compared to syngeneic grafts.
Real-Time PCR
To control the hybridization data, we monitored expression of selected genes in the individual RNAs by real-time quantitative-PCR (Fig. 3) . IFN-␥, and the IFN-␥ induced genes iNOS and indoleamine-2,3-dioxygenase (IDO) are genes that are upregulated in untreated heart allografts as compared to syngeneic controls (PϽ0.01). This upregulation is reversed by CsA, but not by the other treatment regimens (Figure 3 ). CD163 and insulin-like-growth-factor-1 (IGF-1) are examples of genes tending to be repressed in allografts as compared to syngeneic grafts, and this repression is reversed by CsA and both pterins, but not by L-NIL. Statistical analyses using the Kruskal-Wallis test showed significant repression only for IGF-I, all other effects, although visible as a trend, did not reach the significance level with this nonparameteric test (Fig. 3) . The matrix metalloproteinase ADAM10 is an example of a gene not influenced by allogeneic combination or any of the different treatment regimens (Fig. 3) .
Insulinlike growth-factor binding protein-4 (IGF-BP4) was regulated similarly to IGF-1, being repressed in allografts as compared to syngeneic grafts (PϽ0.05), and this repression was attenuated by CsA, BH4 and ABH4, but not by L-NIL (data not shown).
Peroxynitrite Formation
Finally, we checked the influence of the various treatment regimens on intragraft peroxynitrite generation by means of nitrotyrosine staining (Fig. 4) . In untreated allografts, nitrotyrosine staining was enhanced as compared to syngeneic controls. CsA failed to reduce nitrotyrosine staining, whereas all other treatment regimens ABH4, BH4, and L-NIL caused a reduction in nitrotyrosine staining intensity as compared to untreated allogeneic grafts (Fig. 4) . Although clearly visible as a trend, the Kruskal Wallis statistics eomployed throughout this study judges all score difference (Fig.  4 ) not significant.
DISCUSSION
We found that tetrahydrobiopterin, a compound promoting NO formation, but not L-NIL, which is an effective inhibitor of iNOS, significantly prolonged allograft survival. Although the survival curve is more heterogeneous with the tetrahydrobiopterin compounds than with CsA, overall median survival times were not significantly different. However, histological rejection scores revealed that despite prolonged graft survival and good myocardial function all ABH4-treated and BH4-treated hearts showed infiltrates of mononuclear cells and some foci of inflammatory infiltrate, resulting in ISHLT-scores for ABH4 (IIIA to IIIB) and BH4 (IB to IIIA), whereas all CsA-treated grafts displayed almost no cellular infiltrates (ISHLT-score, IA). These findings indicate that the observed increase in graft survival time produced by tetrahydrobiopterin compounds might involve mechanisms other than changes in cellular infiltration. It was previously shown that rejection scores are not always reliable in predicting allograft survival and that there might be a lack of good correlation between histology, T-cell activation, and cytokine gene expression during rejection (20) .
The incapacity of the iNOS inhibitor L-NIL and the efficacy of the iNOS stimulator tetrahydrobiopterin to prolong allograft survival suggests that suppression of NO formation from iNOS apparently plays only a minor role for prolonging allograft survival in our model. These results are in line with the literature showing that iNOS-inhibition or knockout has only minor to moderate effect on allograft survival (7) (8) (9) (21) (22) (23) . A study published while this work was in progress showed that L-NIL added to the drinking water of rats is effective only at low doses that incompletely blocked NO, but not at high doses giving complete ablation of NO formation (24) .
Reduction of ischemia-reperfusion-injury and graft infiltration with monocytes on day 1 posttransplantation by the tetrahydrobiopterin or its precursor sepiapterin has been attributed to a potential inhibition of superoxide formation by NOS by means of decreased uncoupling of the enzyme (25, 26) . In line with this suggestion, we found a trend towards decreased nitrotyrosine staining, a sign of intragraft peroxynitrite formation (27) , in allografts of animals treated with tetrahydrobiopterin. Peroxynitrite-induced nitration has been demonstrated to be associated with numerous injurious effects on cellular and tissue functions in the heart (28). Nitrotyrosine staining, however, was also decreased by L-NIL, which did not prolong allograft survival. In addition, CsA significantly prolonged allograft survival, but did not markedly reduce nitrotyrosine staining, suggesting that nitrotyrosine formation is not directly coupled to decreased allograft survival in our model. Our gene array analysis significantly extends previous work (29 -31) on differences in gene expression in allografts versus syngeneic grafts, and the effect of CsA therapy on this gene expression. We found that CsA treatment was able to counterregulate more than half of the expressional changes observed. Due to its inhibition of calcineurin, CsA inhibits expansion of alloreactive T-cells and T-cell-mediated activation processes, many of which are triggered by IFN-␥ (32). In accordance with this mechanism, we observed suppression of IFN-␥ gene expression and the IFN-␥-induced genes iNOS and IDO. Remarkably, CsA was able to almost completely suppress IFN-␥ expression to levels just above the detection limit of quantitative PCR. In contrast to CsA, the tetrahydrobiopterin compounds did not affect genes associated with activation of the T-cell axis, which is a major target of CsA. In addition, the tetrahydrobiopterin compounds regulated only a surprisingly small number of genes as compared to CsA. This suggests that the tetrahydrobiopterin compounds may exert their effect primarily on the posttranscriptional level. Consistent with this suggestion we found that in cultured murine bone marrow derived dendritic cells 4-amino tetrahydrobiopterin suppresses expression of MHC class II antigen and T-cell stimulatory capacity without affecting MHC class II mRNA levels in the cells (33) . Interestingly, these effects were even more pronounced in cells from iNOS (-,-) mice (33) .
Among the few genes found to be counter-regulated by the pterins is IGF-1, which is repressed during unmodified rejection; this repression is attenuated by the tetrahydrobiopterins as well as by CsA, but not by L-NIL. IGF-1 has been shown to be cardioprotective via an antiapoptotic mechanism in a rat ischemia-reperfusion model (34) . Remarkably, IGF-1 reduction has been observed in tetrahydrobiopterin synthesis-deficient mice (35) . Since IGF-binding-proteins follow the same pattern as IGF-1 expression, however, it is not clear whether the altered IGF-1 expression also results in altered IGF-1 activity in our study.
Experimental pharmacological treatment with tetrahydrobiopterin has thus far been applied to atypical and mild typical forms of phenylketonuria (36) , as well as in treatment of vascular dysfunction (37) . In line with its cardiovascular action, tetrahydrobiopterin prevented CsA -induced vasomotor dysfunction (38) . Our data constitute the first report describing an immunosuppressive action of pharmacologically applied tetrahydrobiopterin.
